Study identifier:NIS-GBA-DUM-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An epidemiological, observational study to describe symptom control and impact on daily life in patients with gastroesophageal reflux disease (GERD)
Gastroesophageal Reflux Disease
-
No
-
All
1233
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Apr 2012 by AstraZeneca
AstraZeneca
-
The purpose of this study is to evaluate symptoms control and impact on daily life from patients perspective using specific GERD Impact Scale(GIS) questionnaire. The another objective is to obtain local epidemiological data for Bosnia and Herzegovina regarding GERD treatment in primary care.
Location
Location
Banja Luka, Bosnia And Herzegovina
Location
Bijeljina, Bosnia And Herzegovina
Location
Derventa, Bosnia And Herzegovina
Location
Doboj, Bosnia And Herzegovina
Location
Gracanica, Bosnia And Herzegovina
Location
Gradacac, Bosnia And Herzegovina
Location
Gradiska, Bosnia And Herzegovina
Location
Hadzici, Bosnia And Herzegovina
Arms | Assigned Interventions |
---|---|
1 | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.